Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2013P000335 | Other Identifier | Partners Human Research Office |
Not provided
Not provided
Not provided
Inability to recruit eligible subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether vilazodone is more effective than citalopram for the treatment of anxious depression. We will use neuroimaging to see whether there are changes in the brains of patients receiving the drug vilazodone that are different from those of citalopram. These changes may show that vilazodone affects the brain differently than most other kinds of standard antidepressant medications.
This study proposes to utilize recent advances in magnetic resonance spectroscopy (MRS) techniques that permit reliable measurement of Glu in humans (9) to examine whether Vilazodone and citalopram exert differential effects on Glutamatergic neurotransmission in the ACC of anxious unipolar depressed patients. Functional connectivity as measured by Blood Oxygen Level Dependent (BOLD) MRI will be assessed to determine the relationship between the change in connectivity and the change in Glu levels with treatment. We also propose to examine, in an exploratory fashion, the relative effect of the two drugs on BOLD activation in the insula cortex.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vilazodone | Experimental | 10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks. |
|
| Citalopram | Active Comparator | 20 mg/day for 2 weeks and then 40 mg/day for 6 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vilazodone | Drug | 10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Glutamate Levels | Our hypothesis that Vilazodone will increase ACC glutamate levels more than Citalopram will be addressed using a repeated measures linear regression model with ACC glutamate level as the outcome and drug (Vilazodone or Citalopram) and drug x scan time (baseline or follow-up) interaction as predictors. | Week 0 and Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Functional Connectivity | Our hypothesis that Vilazodone will decrease functional connectivity more than Citalopram will be addressed using a repeated measures linear regression model with functional connectivity correlation as the outcome and drug (Vilazodone or Citalopram) and drug x scan time (baseline or follow-up) interaction as predictors. | Week 0 and Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in BOLD signal | Exploratory analyses will estimate the effect size of the different treatments on change in BOLD signal. | Week 0 and Week 4 |
| Change in MADRS Score | Associations with change in MADRS score will be quantified by incorporating treatment, change in glutamate level, change in functional connectivity, and their interactions with follow-up time as predictors in repeated measures linear regression models with MADRS scores as repeated outcomes. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael E Henry, MD | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
Not provided
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D001008 | Anxiety Disorders |
| D003866 | Depressive Disorder |
| ID | Term |
|---|---|
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069503 | Vilazodone Hydrochloride |
| D015283 | Citalopram |
| D003909 | Dexetimide |
| ID | Term |
|---|---|
| D010879 | Piperazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001572 | Benzofurans |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Citalopram | Drug | 20 mg/day for 2 weeks and then 40 mg/day for 6 weeks |
|
|
| Screen and Weeks 0, 2, 4, 6, & 8 |
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D007211 | Indoles |
| D011437 | Propylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D009570 | Nitriles |
| D010881 | Piperidones |
| D010880 | Piperidines |